OcuSciences, Inc. announced at ARVO that the FDA has granted marketing clearance for its flagship device, the OcuMet Beacon, a confocal scanning ophthalmoscope designed for infrared (IR) and autofluorescence (AF) imaging of the human retina.
The noninvasive device leverages proprietary illumination and detection technology to capture a naturally occurring retinal fluorescence signature. Its advanced software then visualizes functional changes in retinal metabolism, offering clinicians a new dimension of diagnostic insight.
“The OcuMet Beacon provides clinicians with valuable information in just seconds,” said Kurt Riegger, CEO of OcuSciences, in a news release. “This is a game-changer for the many patients and ophthalmologists who stand to benefit from more precise and deeper insight.”
The OcuMet Beacon is indicated for use with or without dilation, requires no dyes, injections, or physical contact, and delivers results in minutes—making it highly adaptable for routine clinical workflows. With FDA clearance now secured, the device will soon be available in clinics and healthcare institutions across the United States.
Retina specialists attending ARVO noted the potential for the OcuMet Beacon to complement existing imaging modalities and enhance early disease monitoring and treatment decision-making.
Source: Retinal Physician
